Breaking News, Collaborations & Alliances

Avalon Establishes Joint Venture with Arbele

To co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-T and CAR-Natural Killer (NK) cellular therapies

Avalon GloboCare Corp. has entered into a joint venture and exclusive license agreement with Arbele Limited to co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-T and CAR-Natural Killer (NK) cellular therapies.     These unique CAR vector constructs are non-virally engineered, possessing multiple therapeutic targets as well as unique “safety-switch” mechanisms.  Based on Avalon’s extensive hospital network for cellular therapy, together with the Company’s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters